Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.
Jiwei HuangYueming WangHaoran ZhangXiaoyi HuPing WangWen CaiYichu YuanHao ZengJin ZhangWen KongYiran HuangShuo WangJianming GuoQiang WeiWei XuePublished in: Cancer communications (London, England) (2021)